GlassScriptPhysician profile
Paula M Bilica
NPI 1467620260
$41,244.37
in general payments reported to CMS, 2019-2025
36 companies · $7,884 in 2025
The $7,884 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $591 · 2021: $1,390 · 2022: $1,097 · 2023: $9,637 · 2024: $20K · 2025: $7,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Honoraria: $9,435 · Travel and Lodging: $5,718 · Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,670.00 |
| Honoraria | $9,435.00 |
| Travel and Lodging | $5,718.48 |
| Food and Beverage | $1,961.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $36,617.34 | 2020-2025 | Exparel, Iovera, Zilretta |
| Abbvie INC. | $1,501.61 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Daiichi Sankyo INC. | $638.67 | 2019-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $560.15 | 2021-2025 | |
| Organon LLC | $235.30 | 2021-2024 | Nexplanon |
| Astellas Pharma US INC | $177.91 | 2020-2025 | Veozah |
| Pfizer INC. | $141.15 | 2019-2023 | |
| Myovant Sciences INC. | $117.21 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $96.74 | 2019-2022 | |
| Exeltis, USA INC. | $93.81 | 2020-2023 | Slynd |
| Agile Therapeutics, INC. | $91.85 | 2021-2022 | |
| Boston Scientific Corporation | $83.93 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Avion Pharmaceuticals | $78.18 | 2020-2021 | |
| Myriad Women'S Health, INC. | $77.61 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $75.63 | 2023-2025 | Myfembree, Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.74 | 2019-2022 | |
| Therapeuticsmd, INC. | $73.61 | 2019-2022 | |
| Shield Therapeutics INC | $68.84 | 2023-2024 | Accrufer |
| Biogen, INC. | $58.18 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $51.11 | 2024 | Aptima |
| Millicent US INC | $35.55 | 2025 | Intrarosa, Femring, Femlyv |
| Scynexis, INC. | $32.90 | 2022 | |
| Evofem Biosciences, INC. | $31.89 | 2020-2021 | |
| Meditrina | $31.18 | 2023 | |
| Aspira Women'S Health INC | $24.87 | 2019-2024 | Ova1 |
| Lupin INC. | $23.24 | 2019-2021 | |
| Minerva Surgical, INC | $22.78 | 2019 | |
| Coopersurgical, INC. | $20.19 | 2020 | |
| Almatica Pharma LLC | $19.50 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.68 | 2019 | |
| Davol INC. | $16.47 | 2022 | |
| Novo Nordisk INC | $14.32 | 2022 | |
| Allergan, INC. | $14.24 | 2020 | |
| Duchesnay USA Incorporated | $13.64 | 2019 | |
| Kerecis Limited | $13.35 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Bilica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.